论文部分内容阅读
目的比较不同剂量辛伐他汀治疗不稳定性心绞痛(UAP)的临床效果及药物不良反应,探讨大剂量辛伐他汀治疗UAP的可行性。方法 88例UAP患者随机分成观察组与对照组各44例,均常规应用抗心绞痛药物。对照组入院24 h内加辛伐他汀20 mg/d;治疗组入院24 h内加加辛伐他汀40 mg/d,疗程8周。结果观察组总有效率93.18%,高于对照组的86.36%。两组药物不良反应发生率分别为9.09%、6.81%,差异无统计学意义(P>0.05),均未发现伴有CK升高的肌肉疼痛,无ALT与CK升高3倍的病例,血尿素氮、血肌酐、血糖值无显著性变化。结论对UA患者早期常规治疗基础使用40 mg辛伐他汀治疗UAP,临床疗效显著,且安全,耐受性好,具有可行性。
Objective To compare the clinical effects and adverse drug reactions of different doses of simvastatin in the treatment of unstable angina pectoris (UAP) and to explore the feasibility of high-dose simvastatin in the treatment of UAP. Methods A total of 88 patients with UAP were randomly divided into observation group and control group, 44 cases in each group. Anti-angina drugs were routinely used. The control group was given simvastatin 20 mg / d within 24 h after admission. The treatment group was given simvastatin 40 mg / d within 24 h after admission, and the course of treatment was 8 weeks. Results The total effective rate was 93.18% in the observation group, which was higher than 86.36% in the control group. Adverse drug reaction rates in the two groups were 9.09% and 6.81%, respectively, with no significant difference (P> 0.05). No muscle pain accompanied with CK was found, and no cases of elevated ALT and CK by 3 folds, blood Urea nitrogen, serum creatinine, blood glucose no significant change. Conclusions UAS patients treated with 40 mg of simvastatin on the basis of routine early treatment have significant clinical efficacy, safety, and tolerability, and are feasible.